Skip to main content
Start Project

GHMAP

Class IIa pathway in European Union

EU MDR market-access overview for class iia devices. Planning intelligence only — not a regulatory determination, approval, or clinical decision support.

Source trackedEurope
Timelines, fees, and workflow steps on this page are illustrative market-access planning inputs. They are not legal advice, regulatory approval, or a guarantee of registration, reimbursement, or market entry. Professional review with primary-source verification is required before business use.

Regulatory metrics

Planning ranges for this country and device class. Label every figure as illustrative until sources are verified.

Regulatory pathway metrics for Class IIa in European Union
MetricValueStatus
AuthorityEU MDR Notified Body / Competent AuthoritiesSource tracked
Device classClass IIaExample only
Average timeline~270 days / ~9 months (illustrative)To be verified
Local representative requiredYes — European Authorized Representative (if non-EU manufacturer)To be verified
Government / assessment fee~$15,000 USD (illustrative)Source required

Submission workflow

Step-by-step planning outline. Owners and sequence vary by product evidence and authority questions.

  1. 01

    Confirm EU MDR classification

    Apply Annex VIII rules and document Class IIa rationale.

    Owner: Manufacturer

  2. 02

    Implement MDR-compliant QMS

    ISO 13485-aligned QMS covering MDR obligations.

    Owner: Manufacturer

  3. 03

    Compile technical documentation

    General Safety and Performance Requirements, clinical evaluation, PMS/PMCF plans.

    Owner: Manufacturer

  4. 04

    Engage Notified Body

    Select NB, undergo conformity assessment, close nonconformities.

    Owner: Manufacturer / NB

  5. 05

    CE Mark and EUDAMED / AR controls

    Affix CE Mark; appoint EU AR if non-EU manufacturer; maintain vigilance.

    Owner: Manufacturer / AR

Frequently asked questions

Is EU MDR the same as country registration?
CE Mark under MDR enables EU market access subject to national language, UDI, and vigilance rules. Individual member states may still impose language and notification requirements.
Why is govt_fee_usd high?
Notified Body assessment costs dominate Class IIa budgets and are commercial NB fees, not a single EU government stamp fee. Treat the figure as a planning placeholder.

Related market-access pages

Cross-links between pathway pages, country intelligence, and certification primers.

Other European Union classes

Country intelligence

Broader market, reimbursement, and procurement context for European Union.

Open country profile

Related certifications

Convert planning into a scoped GHMAP engagement

Public pathway pages are general context. Product-specific decisions use request-first market entry packages with written scope lock before research begins.

$5,000 · 15 business days after complete intake and scope lock

Full Country Intelligence

Product-specific market-entry decision for one healthcare or MedTech product in one target country. Includes the Decision Report, Evidence & Calculations Workbook, a 60-minute analyst debrief, and one consolidated revision round.

Request Country Intelligence

$7,500 · 20 business days after complete intake and scope lock

Distributor Search & Qualification

Evidence-based distributor search for one defined MedTech or IVD product in one selected country: 10–15 screened candidates, 10 detailed assessments, and 3–5 recommended for outreach when evidence supports it.

Request Distributor Search

Prefer a shorter briefing first? Request a Regulatory Pathway Brief ($1,800).

Market entry packages

Ready to scope European Union?

GHMAP confirms written scope before Country Intelligence or Distributor Search research begins. Payment never auto-approves introductions or workspace access.

Start Country IntelligenceRead disclaimer

Professional review remains part of every GHMAP deliverable.